Predict your next investment

Private Equity
prometheuscapital.cn

See what CB Insights has to offer

Investments

44

Portfolio Exits

2

Funds

1

About Prometheus Capital

Prometheus Capital is a private equity fund with a focus on investments in China companies. The Firm invests mainly in start-up and growth-stage companies which have the potential to become leaders of their own sectors, excluding real estate, infrastructure, and mining sectors. Prometheus Capital is committed to providing professional support and assistance to all their investee companies to accelerate their growth and reach their new peaks. The Firm's focused sectors include but are not limited to energy conservation and environment protection, new material, clean-tech, medical devices and service, retail & consumer, modern agriculture, and high-end manufacturing.

Prometheus Capital Headquarter Location

1605 A Block, Wanda Plaza 93 Jianguo Road, Chaoyang District

Beijing, Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Prometheus Capital News

China Drugmaker Plunges After Wanda Director Doubts Covid Treatment Efficacy

Apr 19, 2022

Wang Sicong (Source: Sohu) The stock price of traditional Chinese medicine-maker Yiling Pharmaceutical plunged after Wang Sicong, founder of Prometheus Capital and director of Wanda Group , reposted a video on April 14 on Weibo that questioned whether the World Health Organization had ever recommended the firm’s Lianhua Qingwen capsules as Covid-19 treatment. Wang commented on the original post: “The China Securities Regulatory Commission should strictly investigate Yiling Pharmaceutical. It’s difficult to see a media outlet that is so rigorous daring to verify and tell the truth in China.” However, on Tuesday, Wang’s Weibo account was blocked and no more posts were available. Yiling Pharmaceutical responded to Wang’s comment later in the day: “Please point out the specific problems and sources of the news and we will provide answers. From clinical trials to specific experimental data, to being included in Covid’s diagnosis and treatment plan, we have complete evidence and reports for the public.” “We have never said on any occasion that the WHO had recommended the drug as Covid-19 treatment,” the drug maker added. Yiling Pharmaceutical was established in 1992 and mainly engages in the research and development, production and sales of traditional Chinese medicine. In 2019, before the outbreak of the pandemic, its largest revenue source was cardiovascular and cerebrovascular medicine, accounting for 53.15% of the total revenue. After the outbreak in 2020, respiratory medicine represented by the Lianhua Qingwen capsules became the company’s largest revenue source. The drug’s revenue increased from 1.703 billion yuan ($266.6 million) in 2019 to 4.255 billion yuan in 2020, an increase of 149.89% year-on-year, accounting for 48.46% of the total revenue. The capsules also promoted the performance growth of Yiling Pharmaceutical. In the first three quarters of 2021, the company’s revenue topped 8.11 billion yuan while its net profit reached 1.224 billion yuan. The stock price of Yiling Pharmaceutical has also fluctuated with the ebb and flow of the trending topic concerning the company. On April 15th, its shares hit limit down  and saw a 6.7 billion yuan of market value lost in one day. Only ten minutes after the market opened again on Tuesday did the company’s share price began to rise, with the highest increase rate of 4.2% to 33.75 yuan per share. Spread the love:

Prometheus Capital Investments

44 Investments

Prometheus Capital has made 44 investments. Their latest investment was in Poke Erchu as part of their Private Equity on January 1, 2022.

CBI Logo

Prometheus Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/27/2022

Private Equity

Poke Erchu

Yes

1

1/26/2022

Seed

Poke Culture

Yes

1

11/23/2021

Series C - III

Rescale

$50M

Yes

5

9/14/2021

Private Equity

Subscribe to see more

Subscribe to see more

10

11/11/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/27/2022

1/26/2022

11/23/2021

9/14/2021

11/11/2019

Round

Private Equity

Seed

Series C - III

Private Equity

Series B

Company

Poke Erchu

Poke Culture

Rescale

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

5

10

10

Prometheus Capital Portfolio Exits

2 Portfolio Exits

Prometheus Capital has 2 portfolio exits. Their latest portfolio exit was Niupu on March 29, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/29/2021

Acquired

1

8/5/2016

IPO

Subscribe to see more

Subscribe to see more

10

Date

3/29/2021

8/5/2016

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

Acquirer

Subscribe to see more

Sources

1

10

Prometheus Capital Fund History

1 Fund History

Prometheus Capital has 1 fund, including Opportune Capital Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Opportune Capital Fund I

$4.31M

1

Closing Date

Fund

Opportune Capital Fund I

Fund Type

Status

Amount

$4.31M

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.